<DOC>
	<DOCNO>NCT02675478</DOCNO>
	<brief_summary>This dose escalation study evaluate safety , tolerability , pharmacokinetics quizartinib Japanese acute myeloid leukemia ( AML ) subject .</brief_summary>
	<brief_title>Phase 1 Study Quizartinib</brief_title>
	<detailed_description />
	<criteria>Relapsed refractory AML AML standard treatment available ECOG Performance Status ( PS ) 0 2 Acute Promyelocytic Leukemia chronic myelogenous leukemia blast phase ( BCRABL fusion gene positive ) History malignancy within 3 year prior enrollment , except curatively treat insitu carcinoma , AML , MDS .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
</DOC>